Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label Study of the Safety and Dosimetry of a 4-Dose Regimen of Escalating Doses of 177Lu-LNC1004 Injection in Adult Patients With Advanced Fibroblast Activation Protein (FAP)-Positive Solid Tumors

NCT05723640 is registered in ClinicalTrials.gov with Yantai LNC Biotechnology Singapore PTE. LTD. as lead sponsor.

NCT NCT05723640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05723640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label Study of the Safety and Dosimetry of a 4-Dose Regimen of Escalating Doses of 177Lu-LNC1004 Injection in Adult Patients With Advanced Fibroblast Activation Protein (FAP)-Positive Solid Tumors
Lead sponsor
Yantai LNC Biotechnology Singapore PTE. LTD.
Phase
Phase 1
Overall status
Completed
Start date
October 3, 2023
Completion date
September 25, 2024
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, unspecified, adult